Skip to main content
. 2020 Mar 6;150(6):1388–1396. doi: 10.1093/jn/nxaa060

TABLE 3.

Fasting serum phospholipid fatty acid concentrations during the dose-escalation course of the seabuckthorn oil augmented in 16:1n–7t in metabolically healthy adults1

Fatty acid, mol% Baseline Week 3 (120 mg 16:1n–7t/d) Week 6 (240 mg 16:1n–7t/d) Week 9 (480 mg 16:1n–7t/d) ANOVA P values
SFA 47.5 ± 2.81 47.3 ± 3.76 47.4 ± 2.65 46.4 ± 1.88 0.358
 10:0 0.01 ± 0.007 0.01 ± 0.004 0.01 ± 0.004 0.01 ± 0.004 0.179
 12:0 0.04 ± 0.01 0.04 ± 0.02 0.05 ± 0.03 0.05 ± 0.02 0.265
 14:0 0.50 ± 0.12 0.45 ± 0.11 0.48 ± 0.11 0.41 ± 0.14 0.052
 15:0 0.24 ± 0.05 0.25 ± 0.06 0.24 ± 0.04 0.23 ± 0.05 0.688
 16:0 28.9 ± 2.36 28.8 ± 2.87 28.8 ± 2.07 28.2 ± 1.41 0.520
 18:0 15.8 ± 1.79 15.7 ± 1.83 15.9 ± 1.63 15.5 ± 1.77 0.575
 20:0 0.22 ± 0.16 0.24 ± 0.18 0.23 ± 0.13 0.22 ± 0.17 0.668
 22:0 1.03 ± 0.16 1.06 ± 0.23 0.99 ± 0.18 1.02 ± 0.19 0.496
 24:0 0.76 ± 0.12 0.81 ± 0.20 0.73 ± 0.11 0.78 ± 0.14 0.215
MUFA 11.7 ± 1.67 11.8 ± 1.60 12.3 ± 1.50 11.7 ± 1.85 0.405
 cis
  14:1n–5 0.01 ± 0.003 0.01 ± 0.002 0.01 ± 0.002 0.01 ± 0.002 0.107
  16:1n–9 0.12 ± 0.03 0.12 ± 0.03 0.13 ± 0.03 0.11 ± 0.04 0.995
  16:1n–7 0.60 ± 0.33a,b 0.54 ± 0.19a,b 0.67 ± 0.25b 0.56 ± 0.22a 0.045
  18:1n–9 8.61 ± 1.43 8.62 ± 1.46 9.00 ± 1.20 8.35 ± 1.64 0.395
  18:1n–7 1.23 ± 0.16a 1.31 ± 0.19a,b 1.35 ± 0.23b 1.43 ± 0.26b 0.001
  20:1n–9 0.11 ± 0.03 0.12 ± 0.03 0.11 ± 0.02 0.11 ± 0.03 0.178
  22:1n–9 0.02 ± 0.01 0.01 ± 0.01 0.02 ± 0.01 0.02 ± 0.01 0.501
  24:1n–9 1.03 ± 0.30 1.04 ± 0.19 0.99 ± 0.12 1.11 ± 0.21 0.465
 trans
  16:1n–9 0.03 ± 0.009 0.03 ± 0.025 0.03 ± 0.009 0.03 ± 0.011 0.442
  16:1n–7 0.15 ± 0.04a 0.16 ± 0.07a,b 0.17 ± 0.03a,b 0.19 ± 0.05b 0.034
  18:1n–10–12 0.03 ± 0.02 0.03 ± 0.03 0.03 ± 0.01 0.02 ± 0.01 0.688
  18:1n–9 0.15 ± 0.05 0.16 ± 0.06 0.14 ± 0.03 0.15 ± 0.05 0.832
  18:1n–7 0.11 ± 0.04 0.13 ± 0.07 0.13 ± 0.02 0.11 ± 0.04 0.413
n–6 PUFA 35.9 ± 2.60 35.8 ± 3.30 35.2 ± 3.15 36.6 ± 2.64 0.297
 cis
  18:2n–6 22.6 ± 2.59 22.4 ± 2.86 22.0 ± 3.17 22.3 ± 2.57 0.743
  18:3n–6 0.10 ± 0.04 0.09 ± 0.04 0.11 ± 0.08 0.08 ± 0.05 0.179
  20:2n–6 0.28 ± 0.05 0.27 ± 0.04 0.27 ± 0.05 0.26 ± 0.05 0.624
  20:3n–6 2.68 ± 0.71 2.55 ± 0.57 2.62 ± 0.73 2.45 ± 0.71 0.556
  20:4n–6 9.69 ± 1.56a 9.91 ± 2.66a,b 9.7 ± 1.79a 10.9 ± 2.08b 0.014
  22:2n–6 0.02 ± 0.008 0.02 ± 0.005 0.02 ± 0.007 0.02 ± 0.008 0.567
  22:4n–6 0.31 ± 0.07 0.30 ± 0.08 0.32 ± 0.09 0.32 ± 0.08 0.519
  22:5n–6 0.23 ± 0.04 0.22 ± 0.07 0.23 ± 0.08 0.24 ± 0.09 0.501
 trans
  18:2n–6 0.16 ± 0.10 0.17 ± 0.15 0.16 ± 0.10 0.11 ± 0.10 0.505
  18:2-CLA 0.02 ± 0.01 0.02 ± 0.02 0.02 ± 0.01 0.02 ± 0.01 0.352
n–3 PUFA 4.19 ± 0.67 4.43 ± 1.38 4.41 ± 1.15 4.72 ± 0.75 0.501
 18:3n–3 0.22 ± 0.07 0.22 ± 0.09 0.21 ± 0.08 0.19 ± 0.06 0.619
 18:4n–3 0.10 ± 0.07 0.11 ± 0.07 0.10 ± 0.07 0.08 ± 0.05 0.457
 20:3n–3 0.04 ± 0.02 0.04 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 0.084
 20:5n–3 0.71 ± 0.3 0.70 ± 0.40 0.75 ± 0.40 0.67 ± 0.30 0.084
 22:5n–3 0.68 ± 0.13 0.70 ± 0.21 0.72 ± 0.22 0.74 ± 0.10 0.716
 22:6n–3 2.45 ± 0.69 2.66 ± 0.91 2.60 ± 0.68 3.00 ± 0.63 0.168
1

n = 13. Values are means ± SDs. Findings were analyzed by a mixed-effects model ANOVA followed by Tukey's test. Labeled means in a row without a common letter differ, P < 0.05. CLA, conjugated linoleic acid.